@article{480708af616640d7915a3dfbf50180b0,
title = "The Development and Impact of Hemostatic Stewardship Programs",
abstract = "The approval of several new clotting factor concentrates and anticoagulation antidotes has resulted in increased complexity and cost of care. A multidisciplinary hemostatic stewardship program is essential to optimize utilization of these resources. This article summarizes the authors{\textquoteright} approach to the stewardship of clotting factor concentrates and anticoagulation antidotes.",
keywords = "Anticoagulation reversal, Hemophilia, Stewardship, Von Willebrand's disease, clotting factor concentrates",
author = "Dane, {Kathryn E.} and Streiff, {Michael B.} and John Lindsley and Montana, {Manuela Plazas} and Satish Shanbhag",
note = "Funding Information: Disclosure Statement: Dr S. Shanbhag reports grants from Luitpold Pharma / Daiichi-Sankyo , outside the submitted work. Dr M.B. Streiff reports personal fees from Bayer, personal fees from CSL Behring, personal fees from Daiichi-Sankyo, grants from Boehringer Ingelheim , personal fees from Pfizer, grants and personal fees from Portola , grants from Roche , personal fees from Paul, Weiss, Rifkind, Wharton & Garrison LLP, personal fees from Lindell and Lavoie LLP, personal fees from Arnold Porter Kaye and Scholer LLP, personal fees from Cunningham Meyer and Vedrine, PC, personal fees from Gallagher & Kennedy, personal fees from Martinez Manglardi, P.A., outside the submitted work. Other authors report no competing interests. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = oct,
doi = "10.1016/j.hoc.2019.05.010",
language = "English (US)",
volume = "33",
pages = "887--901",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "5",
}